Bioinformatics Market to be Swept by Biomarkers between 2020 to 2030

Bioinformatics, as an amalgamation of information science, mathematics, and biology, does extend relentless support to diverse fields of scientific research. It does apply tools for data management, creation of a database, data mining, data warehousing, and so on. The market for bioinformatics is being bolstered by increasing initiatives and monetary help rendered by the governments all across. Moreover, biomarkers and drug discovery are going for bioinformatics.

The bioinformatics market, by product, consists of sequencing platforms (sequence alignment platforms, sequence analysis platforms, sequence manipulation platforms, structural analysis platforms, and others), knowledge management tools (generalized knowledge management tools and specialized knowledge management tools), and bioinformatics software.

By industry, it says molecular medicine, drug development, clinical diagnostics, agriculture, forensic, animal, academics and research, and environment and gene therapy. By sector, it states medical biotechnology (drug discovery & development, clinical diagnostics & precision medicine, and reproductive health), academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, and forensic biotechnology.

By application, the bioinformatics market states preventive medicine, molecular medicine, genomics & drug development, chemoinformatics and drug design, proteomics, transcriptomics, metabolomics, transcriptomics, and various other biotechnological applications. By service, the market spans data analysis (functional and structural) and data integration.

It also needs to be noted that there is a dearth of research personnel needed for appropriate bioinformatics tools. Plus, non-availability on the part of platforms for integrating big data sets coming out of bioinformatics could stall the propagation of bioinformatics.

The major players include Eurofins Scientific, Waters Corporation, Illumina Inc., Thermo Fisher Scientific, QIAGEN, Wuxi NextCODE, BGI, Agilent Technologies, Sophia Genetics, Dassault Systemes, Genebio, ABM Inc., PerkinElmer Inc., ASEBIO, DNAnexus, Inc., Partek, and DNASTAR. On the expansion front, the HANS-GINS Indxx Healthcare Innovation Ucits ETF, in Apr 2019, announced emphasis on development in the sectors inclusive of genome sequencing, nanotechnology, medical devices, robotics, neuroscience, healthcare trackers, bioengineering, and bioinformatics.